Lundbeck plans phase 2 study of Lu AA21004 for treatment of depression

By Lisa Kerner

Charlotte, N.C., June 21 - H. Lundbeck A/S said it plans to begin enrolling the first of 400 patients in a phase 2 study of Lu AA21004 for the treatment of depression.

"Lu AA 21004 is the result of the efforts of Lundbeck Research and Development to design and develop novel psychotropics displaying clear-cut improvements in efficacy without compromising patient tolerability and compliance," the head of development, Anders Gersel Pedersen, said in a company news release.

"Lundbeck scientists have identified a new chemical class of psychotropics, the bis-aryl-sulphanyl amines, which possess distinct properties compared with currently known psychotropics."

The in-vitro pharmacological profile of Lu AA21004 combines potent effects on several serotonin receptors and serotonin transporter proteins, the company said.

Lundbeck develops and markets drugs for the treatment of psychiatric and neurological disorders.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.